Awaiting development: Guidance and quality standards
Showing 111 to 120 of 326
| Title | Type |
|---|---|
| Gambling | Quality standard |
| Gantenerumab for treating early Alzheimer's disease TS ID 10668 | Technology appraisal guidance |
| Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072] | Technology appraisal guidance |
| Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312 | Technology appraisal guidance |
| Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [TS ID 12050] | Technology appraisal guidance |
| Gosuranemab for treating progressive supranuclear palsy [ID1607] | Technology appraisal guidance |
| Gout | Quality standard |
| Govorestat for treating classic galactosemia in people 2 to 65 years TS ID 12071 | Technology appraisal guidance |
| Heart valve disease in adults | Quality standard |
| Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129] | Technology appraisal guidance |